PORTEFEUILLE

Almost 80% of immunotherapy-eligible cancer patients are not responding to approved immunotherapy due to the lack of sensitive and specific biomarkers. At EVIIVE, we are developing a biomarker discovery platform focused on intercepting the ‘WhatsApp’ communication between immune cells and cancer cells in liquid biopsy, enabling the discovery of robust predictive biomarkers to build the next-generation personalized companion diagnostics for precision medicine. Our vision is to make every cancer patient effectively benefit the most from cutting-edge precision medicine.

Our pilot studies were collaborations with academic/clinical partners so far, for the next steps, we are aiming to complete our first collaborative study with one of the leading pharma to generate a pharma standard data package for us to gain industry-standard traction and to enter the regulatory approval process for our first companion diagnostic product (i.e. immunotherapy response prediction). EVIIVE is incorporating in 2024 Q3, with an alpha user (i.e. U.S.-based therapeutics) secured, collaboration with leading pharma and diagnostics providers in contract negotiation. EVIIVE will continue as a companion diagnostics provider for pharma and ultimately for patients in the clinics. Multiple VCs have shown interest in financing our seed funding round to accelerate the business development.